Molecular Imaging
to explore
innovative Targeted Therapy
Molecular imaging has become an indispensable tool in drug discovery.
Charles Truillet's group research at BioMaps laboratory (UPSaclay) is focused on the development of new biocompatible technologies for the detection and treatment of cancer, with a principal emphasis on tumor microenvironment impacts in relation to the immune system.
About Us
OUR GROUP
3 Technicians
1 Engineer
4 PhD Students
3 internships
OBJECTIVES
Identify pronostic and/or predictive biomarkers to understand the evolution of tumor with and without treatment
To study the tumor and immune system (that include also the glial cells) interaction in order to propose adequate therapy.
Projects
Actualités
28 to 29 at Torun (Poland)
Charles Truillet was honored to have been invited by the Polish Society of Nuclear Medicine (Polskie Towarzystwo Medycyny Nuklearnej) to share his research on immunoPET imaging and theranostic applications.
Many thanks to Marek Pruszynski for the invitation
THE TEAM
Charles Truillet
PHD & CEA scientist
Team Leader
Caroline Denis
in vitro and in vivo Technician
Léa Zimmermann
PhD Student
(Immunology, ImmunoPET, Biomarker discovery)
Hélène Quelquejay
CEA Researcher
(RadioImmunoTherapy)
Céline Chevaleyre
PhD student
(Glioblastoma, immunoPET and BBB opening)
Soizic Martin-Aubert
Biochemical Engineer
(Imaging, Binding assay, Proteins)
Benoit Jego
Biochemical/molecular Technician
Goran Stanajic Petrovic
PhD Student
(Toxine, V2R, biomarker discovery)
Anne-Laure Grindel
Postdoctorant student
(Immunology, local immunotherapy)
Dimitri Kereselidze
WildLife biologist Technician
Sophie Tran
PhD Student
(Sonoporation, PSMA, Drug delivery)
Kevin Avrillon
Année Recherche Pharma
(Drug delivery, Tissular distribution, Toxicity)
Publications
BioMaps
The « Paris-Saclay Multimodal Biomedical Imaging Lab » (laBoratoire d’Imagerie biOmédicale MultimodAle Paris Saclay – BioMaps) aims at developing methods, instruments and agents for biomedical imaging and transferring them to clinical applications in oncology and neurology. BioMaps ambition is to become a major actor of research in medical imaging at the interface of physics-chemistry-medicine in Paris-Saclay.
Partners
